DrugPatentWatch Database Preview

DUVELISIB - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for duvelisib and what is the scope of patent protection?

Duvelisib is the generic ingredient in one branded drug marketed by Secura and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Duvelisib has one hundred and thirty-eight patent family members in thirty-one countries.

Summary for DUVELISIB

International Patents:	138
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	61
Clinical Trials:	32
Patent Applications:	1,766
Drug Prices:	Drug price trends for DUVELISIB
What excipients (inactive ingredients) are in DUVELISIB?	DUVELISIB excipients list
DailyMed Link:	DUVELISIB at DailyMed

See drug prices for DUVELISIB

Recent Clinical Trials for DUVELISIB

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alliance for Clinical Trials in Oncology	Phase 2
John Kirkwood	Phase 1/Phase 2
University of Pennsylvania	Phase 2

See all DUVELISIB clinical trials

US Patents and Regulatory Information for DUVELISIB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-002	Sep 24, 2018		RX	Yes	Yes			Y	Y
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-002	Sep 24, 2018		RX	Yes	Yes
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No			Y	Y
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No
Secura	COPIKTRA	duvelisib	CAPSULE;ORAL	211155-001	Sep 24, 2018		RX	Yes	No

International Patents for DUVELISIB

Country	Patent Number	Estimated Expiration
European Patent Office	3441392
Japan	2016135768
Russian Federation	2012105071
Mexico	2013008065
Russian Federation	2513636